Daniel Markgraf
Head of Laboratory Boehringer Ingelheim
Dr. Daniel Markgraf is an accomplished biochemist and research leader currently serving as Principal Scientist, Head of Laboratory and leading interdisciplinary drug discovery projects at Boehringer Ingelheim. With extensive expertise in biomedical analysis and metabolism research, he brings both scientific depth and managerial experience to his role.
Prior to joining Boehringer Ingelheim, Dr. Markgraf held several key positions at leading German diabetes research institutions. He served as Laboratory Head of the Biomedical Analysis & Research Laboratory at the German Diabetes Centre. Additionally, he led the “Stable Isotopes” platform within the German Centre for Diabetes Research (DZD), demonstrating his specialization in advanced research methodologies.
Dr. Markgraf’s academic credentials include postdoctoral training at Harvard Medical School, following the completion of his PhD in Biochemistry at Heidelberg University. His scientific background combines rigorous cell biological and biochemical training with practical expertise in laboratory leadership, innovative research platform development and early drug discovery.
Seminars
- Focusing on energy expenditure mechanisms to complement current appetite-modulating therapeutic approaches
- Discovery and characterization of an adipose tissue-enriched small molecule mitochondrial uncoupler that enhances energy expenditure
- Demonstrating preclinical efficacy and safety by adipose-enriched mitochondrial uncoupling
- Balancing rapid weight loss with microvascular and metabolic health preservation to mitigate rebound effects and enhance reimbursement potential
- Understand regulatory and patient advocacy perspectives to improve trial retention
- Exploring ethical trial design for the next gen-generation of obesity therapies to provide robust evidence for regulatory and commercial success
- Exploring beyond traditional targets to understand how peripheral pathways and novel mechanisms address unmet needs in obesity care
- Integrating multi organ approached from gut-brain signalling with systemic metabolic health for synergistic efficacy to address payer demands, and drive adherence and market access
- Translating preclinical insights into clinically viable non-incretin therapies to diversify obesity drugs and move from placebo to active comparator trials
